Article information
Resumo
A tuberculose é uma doença bem conhecida e para a qual há fármacos de reconhecida eficácia. Em Portugal, a incidência da tuberculose tem vindo a diminuir de forma consistente nos últimos anos, mantendo contudo valores acima da média europeia. Uma nova dificuldade surge, associada à resistência aos antibacilares reconhecidamente relacionada com a não adesão ao tratamento e/ou a uma incorrecta escolha do regime terapêutico. Assim, é importante focar a atenção na abordagem inicial do caso de tuberculose, sendo esse o objectivo desta revisão.
Palavras-chave:
Tuberculose
tratamento
efeitos colaterais
Abstract
Tuberculosis is a well-known illness for which there is treatment of recognized effectiveness. In Portugal, tuberculosis incidence has been diminishing although keeping values higher than the rest of the Western Europe. A new challenge is associated with resistance to drugs, admittedly related to treatment noncompliance or incorrect treatment choice. The purpose of this review to focus our attention on the importante of the first approach to the tuberculosis case.
Key-words:
Tuberculosis
treatment
side effects
Full text is only aviable in PDF
Bibliografia
[1.]
DGS. Programa Nacional de Luta Contra a Tuberculose.
[2.]
D.A. Mitchinson, A.J. Nunn.
Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.
Am Rev Resp Dis, 133 (1986),
[3.]
CDC – National Center for HIV/AIDS, viral hepatitis, STD and TB prevention. Core curriculum on tuberculosis, Chapter 7; 2000 Disponível em: http://www.cdc.gov/tb/pubs/corecurr/Chapter7/Chapter_7.html.
[4.]
New York City Department of Health and Mental Higyene. Tuberculosis – Clinical policies and protocols. 4th Edition, 2008
[5.]
American Thoracic Society Documents.
American Thoracic Society/Centers of Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.
Am J Respir Crit Care Med, 167 (2003), pp. 603-662
[6.]
R.E. Chaisson, H.C. Clermont, E.A. Holt, H.C. Clermont, E.A. Holt, M.P M Johnson, J.. Atkinson, H. Davis, R. Boulos, JHU-CDS Research Team, et al.
Six-months supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection.
Am J Respir Crit Care Med, 154 (1996), pp. 1034-1038
[7.]
T.R. Sterling, K. Alwood, R. Gachuhi, et al.
Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons.
AIDS, 13 (1999), pp. 1899-1904
[8.]
W.M. El-Sadr, D.C. Perlman, E. Denning, J.P. Matts, D.L. Cohn.
A review of efficacy studies of 6-month shortcourse therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes.
Clin Infect Dis, 32 (2001), pp. 623-632
[9.]
J. Murray, P. Sonnenberg, S.C. Shearer, P. Godfrey-Fausett.
Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients.
Am J Respir Crit Care Med, 159 (1999), pp. 733
[10.]
Stop TB Partnership Childhood TB Subgroup.
World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. Chapter 2: anti-tuberculosis treatment in children.
Int J Tuberc Lung Dis, 10 (2006),
[11.]
Grupo de Trabajo de Tuberculosis de la Sociedad Española de Infectología Pediátrica (SEIP).
Treatment of extrapulmonary tuberculosis and complicated forms of pulmonary tuberculosis.
An Pediatr, 69 (2008), pp. 271-278
[12.]
American Thoracic Society Documents.
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.
Am J Respir Crit Care Med, 167 (2003), pp. 603-662
[13.]
N.R. Budha, R.E. Lee, B. Meibohm.
Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs.
Curr Med Chem, 15 (2008), pp. 809-825
[14.]
Bothamley G. Drug treatment for tuberculosis during pregnancy: Safety considerations. Drug Safety 24(7):553–565.
[15.]
World Health Organization. Treatment of tuberculosis: guidelines for national programmes; 2nd edition. 1997.
[16.]
World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO Library Cataloguing-in-Publication Data 2006. Acessível em: http://whqlibdoc.who.int/publications/2006.
[17.]
Zaleskis R. WHO Regional Office for Europe. Postgraduate Course ERS Copenhagen 2005. The side effects of TB therapy. Breathe 2005; 2: 69-73 Acessível em: http://www.ers-education.org/pages/default.aspx?id=610.
[18.]
Direcção-Geral de Saúde. Circular Normativa n.° 19/DSCS/PNT de 17/10/2007 a 2007-10-17. Assunto: Rastreio de infecção VIH nos doentes com tuberculose. Acessível em: http://www.dgs.pt/.
[19.]
L.L. Flores, M. Pai, J.M. Colford Jr., L.W. Riley.
In-house nucleic acid amplification tests for the detection of Mycobacterium tuberculosis in sputum specimens: meta analysis and meta-regression.
BMC Microbiol, 5 (2005), pp. 55
[20.]
F. Antunes, M. Villar, R. Duarte, U. Brito, A. Abreu, et al.
Tuberculose multirresistente Orientações técnicas para o controlo, prevenção e vigilância em Portugal. Conclusões do seminário sobre tuberculose multiresistente.
Direcção-Geral de Saúde, (2008),
Copyright © 2010. Sociedade Portuguesa de Pneumologia
